QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting.

Bhaskar, A and Ramraj, B and Padmapriyadarsini, C and Reddy, D (2023) QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting. QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting., 27(4) (329-31).

Text 202350.pdf - Published Version Download (140kB)

Abstract

Bedaquiline (BDQ) in an optimised background regimen (OBR) achieves early sputum conversion in difficult to treat multidrug-resistant TB (MDR-TB) patients with additional resistance to fluoroquinolones (FQs).1,2 However, BDQ has the potential to affect the QT interval of the cardiac cycle within days or weeks of initiating treatment.2,3 The multi-drug treatment regimen includes other drugs that can also prolong the QT interval with an additive or synergistic effect on QT interval going beyond 500 ms(using either Bazett or Fridericia correction formulae).4,5 This study aimed to characterise effects on the QTc interval when BDQ is used with other drugs to treat drug-resistant TB (DR-TB).

Affiliation:	ICMR-National Institute for Research in Tuberculosis
Item Type:	Article
URI:	http://eprints.nirt.res.in/id/eprint/2222

Actions (login required)

View Item